The CD36-PPARγ Pathway in Metabolic Disorders
1
Research Center, CHU Sainte-Justine, Montréal, QC H3T 1C5, Canada
2
Department of Physiology, Faculty of Medicine, University of Montreal, Montréal, QC H3T 1J4, Canada
3
Department of Biochemistry and Molecular Medicine, Faculty of Medicine, University of Montreal, Montréal, QC H3T 1J4, Canada
4
Centre de Recherche en Reproduction et Fertilité, University of Montreal, Saint Hyacinthe, QC J2S 7C6, Canada
5
Department of Obstetrics & Gynecology, Faculty of Medicine, University of Montreal, Montréal, QC H3T 1C5, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1529; https://doi.org/10.3390/ijms19051529
Received: 8 April 2018
/
Revised: 8 May 2018
/
Accepted: 16 May 2018
/
Published: 21 May 2018
(This article belongs to the Special Issue PPARs in Cellular and Whole Body Energy Metabolism)
Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders.
View Full-Text
Keywords:
scavenger receptor; PPAR nuclear receptors; PGC-1; fatty acid oxidation; energy metabolism; GHRP; hexarelin; atherosclerosis; insulin resistance
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Maréchal, L.; Laviolette, M.; Rodrigue-Way, A.; Sow, B.; Brochu, M.; Caron, V.; Tremblay, A. The CD36-PPARγ Pathway in Metabolic Disorders. Int. J. Mol. Sci. 2018, 19, 1529. https://doi.org/10.3390/ijms19051529
AMA Style
Maréchal L, Laviolette M, Rodrigue-Way A, Sow B, Brochu M, Caron V, Tremblay A. The CD36-PPARγ Pathway in Metabolic Disorders. International Journal of Molecular Sciences. 2018; 19(5):1529. https://doi.org/10.3390/ijms19051529
Chicago/Turabian StyleMaréchal, Loïze, Maximilien Laviolette, Amélie Rodrigue-Way, Baly Sow, Michèle Brochu, Véronique Caron, and André Tremblay. 2018. "The CD36-PPARγ Pathway in Metabolic Disorders" International Journal of Molecular Sciences 19, no. 5: 1529. https://doi.org/10.3390/ijms19051529
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
